阿尔茨海默病的BACE1抑制剂:当前的挑战和未来的前景
Judite R M Coimbra1,2, Rosa Resende2,3, José B A Custódio2,4
1Laboratory of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Coimbra, Coimbra, Portugal.
Journal of Alzheimer's disease : JAD
|June 29, 2024
概括
通过BACE1抑制剂开发有效的阿尔茨海默病 (AD) 治疗方法,以向通过BACE1抑制剂产生粉样β (Aβ),面临着挑战. 未来的抑制剂需要高的基质选择性,以避免副作用,并实现临床成功.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 生物化学 生物化学
背景情况:
- 阿尔茨海默病 (AD) 的发病与粉样ββ (Aβ) 的积累密切相关.
- 酶A$eta$-站点A$eta$PP裂变酶1 (BACE1) 启动A$eta$生产,并且在AD患者中升高.
- BACE1是一种经过验证的药物标,用于降低AD早期的A$eta$水平.
研究的目的:
- 对阿尔茨海默病的BACE1抑制剂设计的演变进行审查.
- 分析已达到高级临床试验阶段的分子及其相关负债.
- 讨论抗粉样蛋白疗法的挑战,以实现临床成功.
主要方法:
- 关于BACE1抑制剂的科学文献和临床试验数据的综述.
- 分析药物设计策略及其对疗效和安全的影响.
- 检查BACE1基质选择性和非目标效应.
主要成果:
- 20年来,小分子BACE1抑制剂的广泛开发.
- 临床试验由于徒劳或安全问题而被中止,通常与非目标抑制 (例如,BACE2) 或基于机制的毒性有关.
- BACE1 抑制剂显示出潜力,但在临床应用中面临重大障碍.
结论:
- 尽管有挫折,BACE1仍然是阿尔茨海默病的有希望的治疗点.
- 开发具有高度基质选择性的BACE1抑制剂至关重要.
- 克服抑制剂特异性和毒性方面的挑战是未来抗粉样蛋白治疗成功的关键.
关键词:
阿尔茨海默氏症是阿尔茨海默氏症的一种疾病.在BACE1中获得BACE1学位.这是一种BACE1抑制剂.粉样蛋白-β-β 的存在.临床试验是指临床试验中的临床试验.改变疾病的疗法.发现药物的发现.更多相关视频
09:47Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches
Published on: December 15, 2023
1.0K
09:33Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
Published on: December 26, 2016
7.9K
相关概念视频
01:22Alzheimer's Disease: Treatment
178
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
178
01:26Alzheimer's Disease: Overview
461
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
461
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
118
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
118
01:30Dementia
110
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
110